Salutary Actions of Nicergoline During Experimental Coronary Artery Occlusion and Reperfusion

  • R. Bolli


Recently, much attention has focussed on the possible beneficial effects of a-adrenergic-blocking agents in acute myocardial ischaemia. Prazosin and phentolamine prevent ventricular fibrillation induced by coronary artery occlusion and reperfusion in cats [1], although they fail to do so in dogs [2]. Minor antiarrhythmic effects of phentolamine have been reported in patients with acute myocardial infarction [3]. More importantly, afterload reduction by phentolamine has been shown to improve haemodynamics in the setting of acute myocardial infarction complicated by left ventricular failure and/or hypertension [4–6]. However, since phentolamine may incresae heart rate [5, 6], its effect on severity of ischaemia remains uncertain [7]. We [2] have previously shown that phentolamine and prazosin fail to improve severity of ischaemia (estimated from intramyocardial C02 tension), coronary collateral blood flow and arrhythmias during acute coronary occlusion in dogs.


Ventricular Tachycardia Coronary Occlusion Aortic Pressure Ergot Alkaloid Coronary Artery Occlusion 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Sheridan DJ, Penkoske PA, Sobel BE, Corr PB (1980) Alpha adrenergic contributions to dysrhythmia during myocardial ischemia and reperfusion in cats. J Clin Invest 65: 161PubMedCrossRefGoogle Scholar
  2. 2.
    Bolli R, Fisher DJ, Taylor AA, Young JB, Miller RR (1984) Effect of alpha-adrenergic blockade on arrhythmias induced by acute myocardial ischemia and reperfusion in the dog. J Mol Cell Cardiol 16: 1101PubMedCrossRefGoogle Scholar
  3. 3.
    Gould L, Reddy CVR, Weinstein T, Gomprecht RF (1975) Antiarrhythmic prophylaxis with phentolamine in acute myocardial infarction. J Clin Pharmacol 15: 191Google Scholar
  4. 4.
    Chatteijee K, Parmley WW, Ganz W, Forrester J, Walinsky P, Crexells C, Swan HJC (1973) Hemodynamic and metabolic responses to vasodilator therapy in acute myocardial infarction. Circulation 48: 1183Google Scholar
  5. 5.
    Perret C, Gardaz JP, Reynaert M, Grimbert F, Enrico JF (1975) Phentolamine for vasodilator therapy in left ventricular failure complicating acute myocardial infarction: Hemodynamic study. Br Heart J 37: 640PubMedCrossRefGoogle Scholar
  6. 6.
    Kelly DT, Delgado CE, Taylor DR, Pitt B, Ross RS (1973) Use of phentolamine in acute myocardial infarction associated with hypertension and left ventricular failure. Circulation 47: 729PubMedGoogle Scholar
  7. 7.
    Bolli R (1982) Protection of ischemic myocardium in experimental animals and in man: a review. Cardiovasc Res Ctr Bull 21: 1 - 33Google Scholar
  8. 8.
    Arcari G, Dorigotti L, Fregman CB, Glasser AH (1968) Vasodilating and alpha receptor blocking activity of a new ergoline derivative. Br J Pharmacol 34: 700Google Scholar
  9. 9.
    Arcari G, Bernardi L, Bosigio G, Coda S, Fregnan GB, Glasser AH (1972) 10-methoxyergoline derivatives as a-adrenergic blocking agents. Experientia 28: 819PubMedCrossRefGoogle Scholar
  10. 10.
    Huguet F, Biziere K, Breteau M, Narcisse G (1980) Effets de la nicergoline sur divers neu-rorecepteurs centraux: Profil neurochimique. J Pharmacol 11: 257Google Scholar
  11. 11.
    Pornin M, Roland E, Lardoux H, Sellier P, Ourbak P, Maurice P (1980) Effets hemodyna- miques de la prazosine orale et de la nicergoline intraveneuse dans l’insuffisance cardiaque chronique. Ann Cardiol Angeiol (Paris) 29: 379Google Scholar
  12. 12.
    Boismare F, Lefrancois J (1980) Hemodynamic effects of nicergoline in man at rest and during exercise. Clin Exp Pharmacol Physiol 7: 105PubMedCrossRefGoogle Scholar
  13. 13.
    Merillon JP, Morgant C, Lerallut JF, Chastre J, Motte G, Gourgon R (1981) Modifications des propriétés physiques du système arteriel et de l’impedance aortique après nicergoline dans l’insuffisance cardiaque et l’hypertension arterielle permanente. In: Boismare F, Cambier J, Gourgon R, Letac B, Safar M, Schmitt M (eds) Les alpha-bloquants. Pharmacologie experimentale et clinique (International Symposium). Masson, Paris, p 100Google Scholar
  14. 14.
    Schmitt H, Laubie M, Fenard S (1971) Effets hemodynamiques des alcaloides de l’ergot de seigle. J Pharmacol 2: 131Google Scholar
  15. 15.
    Bolli R, Ware JA, Brandon TA, Weilbaecher DG, Mace ML (1984) Platelet-mediated thrombosis in stenosed canine coronary arteries: inhibition by nicergoline, a platelet-active alpha-adrenergic antagonist. J Am Coll Cardiol 3: 1417PubMedCrossRefGoogle Scholar
  16. 16.
    Migne J, Saint-Maurice JP, Santonja R, Kunz S (1974) Activité anti-agregante plaquettaire. Effets d’un alpha-bloquer: La nicergoline. Sem Hop Paris 10: 649Google Scholar
  17. 17.
    LeMenn R, Migne J, Prost-Dvojakovie RJ (1977) Etude ultrastructurale de l’action d’un an- ti-agregant sur les plaquettes sanguines. Application a la nicergoline. Therapie 32: 205Google Scholar
  18. 18.
    Lagarde M, Guichardant M, Chazi I, Dechavanne M (1980) Nicergoline, an anti-aggregat- ing agent which inhibits release of arachidonic acid from human platelet phospholipids. Prostaglandins 19: 551PubMedCrossRefGoogle Scholar
  19. 19.
    Rafelson ME, Migne J, Santonja R, Derouette JC, Robert L (1980) Effect of an alpha-blocking agent, nicergoline, on the interaction between blood platelets, elastin and endothelial cells. Biochem Pharmacol 19: 943CrossRefGoogle Scholar
  20. 20.
    Pogliani E, Della Volpe A, Ferrari R, Recalcati P, Praga C (1975) Inhibition of human platelet aggregation by oral administration of nicergoline. A double-blind study. Farmaco 30: 630Google Scholar
  21. 21.
    Bolli R, Brandon TA, Luck JC, Miller RR, Entman ML (1983) Deleterious effects of incomplete myocardial reperfusion on ventricular arrhythmias. J Am Coll Cardiol 1: 1111–1118PubMedCrossRefGoogle Scholar
  22. 22.
    Bolli R, Goldstein RE, Davenport N, Epstein SE (1981) Influence of sulfinpyrazone and naproxen on infarct size in the dog. Am J Cardiol 47: 841–847PubMedCrossRefGoogle Scholar
  23. 23.
    Bolli R, Kuo LC, Roberts R (1984) Influence of acute arterial hypertension on myocardial infarct size in dogs without left ventricular hypertrophy. J Am Coll Cardiol 4: 522PubMedCrossRefGoogle Scholar
  24. 24.
    Khuri SF, O’Riordan J, Flaherty JT, Brawley RK, Donahoo JS, Gott VL (1975) Mass spectrometry for the measurement of intramyocardial gas tensions: Methodology and application to the study of myocardial ischemia. In: Roy PE, Rona G (eds) Recent advances in studies on cardiac structure and metabolism, vol 10. University Park Press, Baltimore, p 539Google Scholar
  25. 25.
    Khuri SF, Flaherty JT, O’Riordan JB, Pitt B, Brawley RK, Donahoo JS, Gott VL (1975) Changes in intramyocardial ST segment voltage and gas tensions with regional myocardial ischemia in the dog. Circ Res 37: 455PubMedGoogle Scholar
  26. 26.
    Bolli R, Brandon TA, Risher DJ, Miller RR (1982) Ischemic determinants of ventricular arrhythmias during coronary artery occlusion and reperfusion (abstract). Clin Res 30: 174AGoogle Scholar
  27. 27.
    Lievre M, Ollagnier M, Faucon G (1979) Influence of nicergoline on cerebral blood flow and sympatholytical properties. Arzneimittelforsch 29: 1227PubMedGoogle Scholar
  28. 28.
    Nickerson H, Hollenberg NN (1967) Blockade of oc-adrenergie receptors. In: Root WS, Hoffmann FG (eds) Physiological pharmacology. Academic, London, p 243Google Scholar
  29. 29.
    Venu RDL (1978) Clinical pharmacology of ergot alkaloids in senile cerebral insufficiency. In: Berde B, Schild HO (eds) Ergot alkaloids and related compounds. Springer, Berlin Heidelberg New York, p 558 (Handbook of experimental pharmacology, vol 49 )Google Scholar
  30. 30.
    Levenson JA, Roland E, Toto Mou Kouo J, Simon A, Safar M (1980) Action intraveineuse de la nicergoline dans l’hypertension arterielle. Rev Med Interne 1: 123PubMedCrossRefGoogle Scholar
  31. 31.
    Clark BJ, Chu D, Aelling WH (1978) Actions on the heart and circulation. In: Berde B, Schild HO (eds) Ergot alkaloids and related compounds. Springer, Berlin Heidelberg New York, p 356 (Handbook of experimental pharmacology, vol 49 )Google Scholar
  32. 32.
    Bolli R, Brandon TA, DeBauche TL, Miller RR (1982) Alpha-adrenergic blockade does not prevent spontaneous platelet-mediated thrombosis in stenosed coronary arteries ( Abstract ). Am J Cardiol 49: 976CrossRefGoogle Scholar
  33. 33.
    Neill WA, Phelps NC, Oxendine JM, Mahler DJ, Sim DN (1973) Effect of heart rate on coronary blood flow distribution in dogs. Am J Cardiol 32: 306PubMedCrossRefGoogle Scholar
  34. 34.
    Becker L (1976) Effect of tachycardia on left ventricular blood flow distribution during coronary occlusion. Am J Physiol 230: 1072PubMedGoogle Scholar
  35. 35.
    Brown BG, Gundel WD, Gott VL, Covell JW (1974) Coronary collateral flow following acute coronary occlusion: a diastolic phenomenon. Cardiovasc Res 8: 621PubMedCrossRefGoogle Scholar
  36. 36.
    Grayson J, Irvine M, Parratt JR, Cunningham J (1968) Vasospastic elements in myocardial infarction following coronary occlusion in the dog. Cardiovasc Res 2: 54PubMedCrossRefGoogle Scholar
  37. 37.
    Forrester JS, Diamond G, Chatteijee K, Swan HJC (1976) Medical therapy of acute myocardial infarction by application of hemodynamic subsets. N Engl J Med 295: 1356PubMedCrossRefGoogle Scholar
  38. 38.
    Bolli R, Brandon TA, Weilbaecher DG, Mace ML (1985) Influence of alpha-adrenergic blockade on platelet-mediated thrombosis in stenosed canine coronary arteries. Cardiovas Res 19: 146CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1986

Authors and Affiliations

  • R. Bolli
    • 1
  1. 1.Experimental Animal Laboratory, Cardiology SectionBaylor College of MedicineHoustonUSA

Personalised recommendations